EmCare’s parent company receives a “sell” rating from Zacks: 3 points

Envision Healthcare, the parent company of EmCare, received a “sell” rating for the short term from Zacks, according to an American Trade Journal report.

Advertisement

Here are three points:

1. Fourteen analysts have given Envision Healthcare stock a near short term price target of $38.29

2. The 52-week high of the share price is $45.95 and the 52-week low is $20.33.

3. The company has a market cap of $4.77 billion.

More articles on anesthesia:
National Health Council names ASA CEO Paul Pomerantz treasurer: 3 points
Weill Cornell Medical College names Dr. Sheida Tabaie the anesthesia department’s Global Health Fellow: 4 points
A kidney donor death highlights the dangers of anesthesia — 4 things to know

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Advertisement

Next Up in Anesthesia

  • Anesthesiologist pay keeps climbing even as the reimbursement underneath it keeps shrinking, which is a gap ASCs are increasingly bridging…

  • The Morgantown-based West Virginia University School of Nursing is increasing its Doctor of Nursing Practice Nurse Anesthetist program from 15…

Advertisement

Comments are closed.